Elliana Kirsh1, Matthew Naunheim1,2, Allison Holman3, Rachel Kammer3, Mark Varvares1,2, Tessa Goldsmith3. 1. Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, U.S.A. 2. Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts, U.S.A. 3. Department of Speech, Language, and Swallowing Disorders, Massachusetts General Hospital, Boston, Massachusetts, U.S.A.
Abstract
OBJECTIVE: The primary objective of this project was to retrospectively investigate the relationship between patient-reported and physiologic swallowing measures after chemoradiation therapy for head neck cancer (HNC). METHODS: Adult patients who underwent chemoradiation therapy for HNC and presented for videofluoroscopic swallow study were reviewed retrospectively. Surgically treated patients were excluded. Patient perception of swallowing-related outcomes was assessed via the MD Anderson Dysphagia Inventory (MDADI) on the same day that physiologic measures of swallow function were obtained. Using vidoefluoroscopic data, the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) scale yielded measures of safety (DIGEST-S: penetration/aspiration) and efficiency (DIGEST-E: residue). Statistical analysis for correlation coefficients was performed. RESULTS: Thirty patients met the inclusion criteria. The oropharynx was the most commonly affected site (70.0%), followed by the larynx (16.7%). The median radiation dose was 72 grays (Gy), and participants were assessed a mean of 4.6 (range 0-12) years following completion of treatment. There was no correlation between the MDADI and the DIGEST-E score (Pearson rho = -0.045, P = 0.812), DIGEST-S score (Pearson rho = 0.075, P = 0.695), or summary DIGEST grade (Pearson rho = 0.046, P = 0.810). MDADI scores did not change significantly with increasing time since radiation (P = 0.375), whereas the DIGEST-E scores, DIGEST-S score, and summary DIGEST grades worsened over time (P = 0.007, P = 0.002, and P = 0.0005, respectively). CONCLUSION: Assessment of swallowing physiology showed that function worsened after chemoradiation therapy, but this did not correlate with patient-reported quality-of-life measures. Reduced patient awareness of swallow dysfunction years after completion of chemoradiation has implications for management of dysphagia in the face of physiologic decline. LEVEL OF EVIDENCE: 4 Laryngoscope, 129:2059-2064, 2019.
OBJECTIVE: The primary objective of this project was to retrospectively investigate the relationship between patient-reported and physiologic swallowing measures after chemoradiation therapy for head neck cancer (HNC). METHODS: Adult patients who underwent chemoradiation therapy for HNC and presented for videofluoroscopic swallow study were reviewed retrospectively. Surgically treated patients were excluded. Patient perception of swallowing-related outcomes was assessed via the MD Anderson Dysphagia Inventory (MDADI) on the same day that physiologic measures of swallow function were obtained. Using vidoefluoroscopic data, the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) scale yielded measures of safety (DIGEST-S: penetration/aspiration) and efficiency (DIGEST-E: residue). Statistical analysis for correlation coefficients was performed. RESULTS: Thirty patients met the inclusion criteria. The oropharynx was the most commonly affected site (70.0%), followed by the larynx (16.7%). The median radiation dose was 72 grays (Gy), and participants were assessed a mean of 4.6 (range 0-12) years following completion of treatment. There was no correlation between the MDADI and the DIGEST-E score (Pearson rho = -0.045, P = 0.812), DIGEST-S score (Pearson rho = 0.075, P = 0.695), or summary DIGEST grade (Pearson rho = 0.046, P = 0.810). MDADI scores did not change significantly with increasing time since radiation (P = 0.375), whereas the DIGEST-E scores, DIGEST-S score, and summary DIGEST grades worsened over time (P = 0.007, P = 0.002, and P = 0.0005, respectively). CONCLUSION: Assessment of swallowing physiology showed that function worsened after chemoradiation therapy, but this did not correlate with patient-reported quality-of-life measures. Reduced patient awareness of swallow dysfunction years after completion of chemoradiation has implications for management of dysphagia in the face of physiologic decline. LEVEL OF EVIDENCE: 4 Laryngoscope, 129:2059-2064, 2019.
Authors: Sallie M Long; Annu Singh; Amy L Tin; Bridget O'Hara; Marc A Cohen; Nancy Lee; David G Pfister; Tony Hung; Richard J Wong; Andrew J Vickers; Cherry L Estilo; Jennifer R Cracchiolo Journal: JAMA Otolaryngol Head Neck Surg Date: 2022-08-01 Impact factor: 8.961
Authors: R Jordan Hazelwood; Kent E Armeson; Elizabeth G Hill; Heather Shaw Bonilha; Bonnie Martin-Harris Journal: Dysphagia Date: 2022-10-13 Impact factor: 2.733
Authors: Hanne Massonet; Ann Goeleven; Leen Van den Steen; Alice Vergauwen; Margot Baudelet; Gilles Van Haesendonck; Olivier Vanderveken; Heleen Bollen; Lisette van der Molen; Fréderic Duprez; Peter Tomassen; Sandra Nuyts; Gwen Van Nuffelen Journal: Trials Date: 2022-10-22 Impact factor: 2.728
Authors: Matthew R Naunheim; Jennifer B Dai; Benjamin J Rubinstein; Leanne Goldberg; Alan Weinberg; Mark S Courey Journal: Laryngoscope Investig Otolaryngol Date: 2019-12-17
Authors: Danila Rodrigues Costa; Paulo Sérgio da Silva Santos; Cássia Maria Fischer Rubira; Giédre Berretin-Felix Journal: SAGE Open Med Date: 2020-12-14